You are here:

losartan (Cozaar)

Advice

following a full submission:

losartan (Cozaar) is accepted for restricted use within NHS Scotland to delay the progression of renal disease and to reduce proteinuria in type 2 diabetic patients with nephropathy.

Losartan, for the management of renal disease in patients with hypertension and type 2 diabetes mellitus, is effective, but has not been shown to be any more effective than ACE inhibitors, which are generally less expensive products, and for which there is a strong evidence base in diabetic renal disease and other forms of cardiovascular disease. Therefore, losartan should be considered, along with other angiotensin II antagonists licensed for diabetic renal disease, as an alternative in patients unable to tolerate an ACE inhibitor.

Drug Details

Drug Name: losartan (Cozaar)
SMC Drug ID: 131/04
Manufacturer: MSD
Indication: treatment of hypertensive patients with left ventricular hypertrophy.
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 November 2004

Archived Advice

Full submission 9 August 2004

Back